Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will host a conference call and webcast on the same day at 4:30 PM Eastern Time to discuss its performance. Investors can access the webcast via the company's Investor Center website.
JPMorgan Chase & Co. Sells 203,183 Shares of Tandem Diabetes Care, Inc. $TNDM
JPMorgan Chase & Co. reduced its stake in Tandem Diabetes Care, Inc. by 36.1% in the third quarter, selling 203,183 shares and now owning 359,071 shares valued at $4.36 million. Despite beating earnings estimates for the quarter, Tandem Diabetes Care remains unprofitable. Analyst sentiment is mixed, with a "Hold" consensus rating, but some firms have upgraded the stock.
Tandem Diabetes Care to Announce Q1 2026 Results on May 7
Tandem Diabetes Care, a leading company in insulin delivery and diabetes technology, will release its first quarter 2026 financial and operating results on Thursday, May 7, 2026, after the market closes. The company will also host a conference call and webcast on the same day to discuss these results. This announcement is significant for investors and analysts as it offers key insights into the company's performance and broader industry trends in diabetes management.
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will release its first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The company will also host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss these results. Details for accessing the webcast and conference call are provided, including a link for dial-in and information on accessing the archive.
Tandem Diabetes Care Stock Hits Day Low Amid Price Pressure at $20.93
Tandem Diabetes Care, Inc. experienced significant stock volatility on March 27, 2026, with a 9.95% decline, reaching an intraday low of $20.93. The stock has seen substantial drops over the past week and month, and long-term trends show a considerable decline over three and five years. Financial challenges include a low return on equity, a high debt-equity ratio, and dwindling cash reserves.
[SCHEDULE 13G/A] TANDEM DIABETES CARE INC Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for Tandem Diabetes Care, reporting 0 shares beneficially owned. This change is due to an internal realignment under SEC Release No. 34-39538, where certain subsidiaries will now report separately. This filing indicates a structural reporting change rather than an economic transaction like a sale or acquisition of securities.
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into possible securities fraud involving Tandem Diabetes Care, Inc. The investigation follows a significant drop in Tandem's stock price on August 7, 2025, after the company disclosed a malfunction in its insulin pumps that could lead to discontinued insulin delivery and hyperglycemia. Investors are encouraged to contact the firm to discuss potential legal action.
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into potential securities fraud involving Tandem Diabetes Care, Inc. This follows a significant 19.9% stock price drop on August 7, 2025, after Tandem disclosed a malfunction in its insulin pumps that could cease insulin delivery and lead to hyperglycemia. The firm is encouraging affected investors to contact them regarding their legal rights.
Mizuho maintains Tandem Diabetes Care (TNDM) neutral recommendation
Mizuho has reiterated its neutral recommendation for Tandem Diabetes Care (TNDM), reflecting analysts' current stance on the company. This suggests Mizuho is neither bullish nor bearish on TNDM's stock performance at this time.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received a consensus "Hold" rating from nineteen analysts, with an average 1-year price target of $29.22. Although the company beat Q4 earnings estimates, it remains unprofitable. Institutional investors have significantly increased their holdings in Tandem Diabetes Care.
Assenagon Asset Management S.A. Invests $26.99 Million in Tandem Diabetes Care, Inc. $TNDM
Assenagon Asset Management S.A. has invested significantly in Tandem Diabetes Care, Inc. by purchasing 1,227,856 shares, valued at approximately $26.99 million. This acquisition gives Assenagon about 1.81% ownership in the medical device company. Despite mixed Wall Street sentiment, with a consensus "Hold" rating, several analysts have upgraded or raised price targets for Tandem Diabetes Care, which recently beat quarterly revenue and EPS estimates.
Truist Financial Upgrades Tandem Diabetes Care (NASDAQ:TNDM) to "Buy"
Truist Financial upgraded Tandem Diabetes Care (NASDAQ:TNDM) from a "hold" to a "buy" rating, increasing its price target to $35.00, suggesting a potential upside of 46.75%. Despite beating earnings and revenue estimates, the company remains unprofitable, with a consensus "Hold" rating across analysts and a target price of $29.22. Institutional investors, including Vanguard Group Inc., have recently increased their holdings in Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 5.3% on Analyst Upgrade
Tandem Diabetes Care (NASDAQ:TNDM) saw its stock price jump by 5.3% following an analyst upgrade from Truist Financial, which raised its price target to $35.00. The company also reported strong quarterly earnings, beating analyst estimates with EPS of ($0.01) against a consensus of ($0.05) and a 15.1% year-over-year revenue increase. Increased institutional interest, including BNP Paribas significantly boosting its stake, further supported the stock's rise, although the average analyst rating remains a "Hold."
Tandem upgraded at Truist on pharmacy model (TNDM:NASDAQ)
Tandem Diabetes Care (TNDM) saw its shares rise after Truist upgraded the insulin pump maker to Buy from Hold. This upgrade is attributed to the company's new pay-as-you-go pharmacy channel strategy, making Truist the latest firm to positively reassess TNDM based on this model.
US875372AE4 Bond Analysis — Key Metrics
This article provides key metrics for the US875372AE4 bond issued by Tandem Diabetes Care, Inc. It details the bond's issuer, issue date (February 27, 2026), maturity date (March 15, 2032), outstanding amount ($300 million USD), face value ($1,000 USD), and its 0% coupon rate. The company profile highlights Tandem Diabetes Care's focus on products for insulin-dependent diabetes, including the Tandem Mobi System and t:slim X2 Insulin Pump.
US875372AE4 Bond Price and Chart — FWB:US875372AE4
This article provides an overview of the US875372AE4 bond issued by Tandem Diabetes Care, Inc. The bond has a 0% coupon, matures on March 15, 2032, and has an outstanding amount of $300 million USD. It includes key terms, company information, and an invitation to unlock advanced bond data.
Tandem Diabetes Care, Inc. (TNDM) reports Q4 loss, tops revenue estimates
Tandem Diabetes Care (TNDM) reported a Q4 loss of $0.62 per share, which was wider than the Zacks Consensus Estimate but a significant improvement from the previous year. The company's revenue of $197.6 million surpassed analyst expectations and also grew year-over-year. Despite the revenue beat, the stock opened lower following the announcement.
Tandem Diabetes (TNDM) EVP exercises 7,414 RSUs and sells 187 shares
Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark David Novara, exercised 7,414 Restricted Stock Units, resulting in the vesting of common shares under the company's 2023 Long-Term Incentive Plan. To cover taxes, 5,540 shares were withheld by the company, and Novara also made a separate pre-scheduled open-market sale of 187 common shares at $23.05 each. After these transactions, Novara directly holds 37,656 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Piper Sandler
Piper Sandler upgraded Tandem Diabetes Care (NASDAQ:TNDM) from "neutral" to "overweight" with a raised price objective of $33, suggesting a 50.6% upside. This upgrade follows better-than-expected quarterly results, though the company remains unprofitable. Analyst coverage generally presents a "Hold" rating with an average target price of $28.78.
Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up on Analyst Upgrade
Tandem Diabetes Care (NASDAQ:TNDM) shares gapped up following an analyst upgrade from Piper Sandler, changing their rating from neutral to overweight and raising the price target to $33. The company recently exceeded quarterly revenue and EPS estimates, reporting $290.38M in revenue and -$0.01 EPS, despite remaining unprofitable with a negative net margin. Analysts currently have an average "Hold" rating on TNDM with a consensus target price of $28.78.
How Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Mobi Control To Android Smartphones
Tandem Diabetes Care recently expanded control of its Mobi automated insulin delivery system to Android smartphones, following FDA clearance in November 2025. This move aims to broaden user access and strengthen the company's position in the diabetes management market, despite facing ongoing competition and net losses. While analysts anticipate potential revenue growth and an improved investment narrative, the company still navigates flat renewal expectations and commercial transformation risks.
The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Android Launch Of Tandem Mobi App
Tandem Diabetes Care (TNDM) recently made its FDA-cleared Tandem Mobi app available to U.S. Android users, allowing direct control of its insulin delivery system from select Android smartphones. This expansion could significantly impact Tandem's investment narrative by broadening its user base and potentially improving renewal rates, though the company still faces challenges with profitability and competition. Investors will be watching if this move helps Tandem meet its 2026 revenue guidance and improve its financial outlook.
Piper Sandler Upgrades Tandem Diabetes Care (TNDM) to Overweight
Piper Sandler has upgraded Tandem Diabetes Care (TNDM) from 'Neutral' to 'Overweight', significantly raising its price target from $21.00 to $33.00, representing a 57.14% increase. This bullish outlook comes amid other recent analyst rating changes and price target adjustments for the diabetes device manufacturer. Wall Street analysts currently project an average target price of $30.36 for TNDM, implying an upside of 38.58% from its current price, while GuruFocus estimates a fair value of $35.12.
Tandem Diabetes Care (TNDM) insider files resale notice; 2 shares sold at $45.62
A Tandem Diabetes Care (TNDM) insider has filed a Form 144 notice for a proposed resale of 187 shares originating from Restricted Stock Units, effective March 15, 2026. The filing also reports a small 10b5-1 sale of 2 shares at $45.62 on March 5, 2026, by Mark Novara through Morgan Stanley Smith Barney LLC. This filing is considered routine given the small quantity of shares involved.
Tandem Diabetes Care Stock Upgrade & Market Outlook 2026 - News and Statistics
Shares of Tandem Diabetes Care (TNDM) rose after Piper Sandler upgraded the company's stock and set a higher price target, contributing to positive market sentiment. Despite this recent gain, the stock has experienced significant volatility and is still below its earlier peak, with a five-year investment showing a decline in value. The article also includes extensive details about a global syringe industry report, forecasting demand, supply, and trade flows to 2035.
TNDM Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Tandem Diabetes Care Inc (TNDM), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from its Pump segment, and its financial health is assessed through metrics like gross margin, operating margin, and return on equity. TNDM's performance is benchmarked against industry peers like PLSE and ATRC.
Piper Sandler Upgrades Tandem Diabetes Care (TNDM) to Overweight | TNDM Stock News
Piper Sandler has upgraded Tandem Diabetes Care (TNDM) from 'Neutral' to 'Overweight', significantly raising its price target from $21.00 to $33.00, an increase of 57.14%. This upgrade reflects a strong bullish outlook for the company, which designs and manufactures insulin pumps. The average analyst price target for TNDM is now $30.36, indicating a potential upside of 38.58% from its current price.
Assessing Tandem Diabetes Care (TNDM) Valuation After Mixed Long Term Returns And Recent Share Price Strength
Tandem Diabetes Care (TNDM) has shown mixed share performance, with recent gains but deeply negative long-term returns. Despite a current undervaluation narrative at $28.91 (versus $21.59 share price) driven by product pipeline optimism, execution risks and intensifying competition could challenge future growth. Investors are advised to review financials, consider stronger fundamental companies, and explore undervalued or resilient stocks.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
Tandem Diabetes Care, Inc. (TNDM) is highlighted as a stock to hold due to its impressive product innovations, including new insulin pump software compatible with various CGM systems and the launch of Tandem Mobi. The company also demonstrates strong solvency. However, competitive pressures and macroeconomic challenges pose potential headwinds, with a reported net loss in the fourth quarter of 2025.
[144] TANDEM DIABETES CARE INC SEC Filing
This article reports on an SEC Form 144 filing by Tandem Diabetes Care Inc. (TNDM) concerning a proposed sale of securities. The filing details the sale of 2 shares of common stock with an aggregate market value of $46.82 by an executive using Morgan Stanley Smith Barney LLC, acquired as Restricted Stock Units on February 15, 2026. The document confirms that no securities were sold by the filer in the past three months.
Tandem Diabetes Care, Inc. $TNDM Position Trimmed by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Tandem Diabetes Care (TNDM) by 4.2% in the third quarter, selling 306,516 shares but still holding a significant 10.45% stake valued at $85.75 million. Despite analysts having a mixed "Hold" consensus with an average target price of $28.11, the company reported better-than-expected earnings for the latest quarter though it remains unprofitable. Other institutional investors showed varied activity, with some increasing and others acquiring new positions in TNDM.
Tandem Diabetes expands Mobi Insulin Pump to Android users
Tandem Diabetes Care Inc. has expanded its Mobi automated insulin delivery system to include compatibility with Android smartphones, making it accessible to a wider range of users beyond the initial iPhone-only launch. The FDA-cleared technology, powered by Control-IQ+, is available on select Google Pixel and Samsung Galaxy models, offering users improved time-in-range for glucose levels and a compact, discreet pump design. This move reflects a broader industry trend toward smartphone-controlled, miniaturized, and highly effective automated insulin delivery systems.
Tandem Diabetes adds Android support for Mobi insulin pump
Tandem Diabetes Care, Inc. has expanded its Mobi automated insulin delivery system to include compatibility with Android smartphones in the U.S., through the Tandem Mobi mobile app. This move broadens the accessibility of their Control-IQ+ technology, previously available only on iPhones, to a larger user base. The company recently increased its convertible senior notes offering to $265 million and has seen positive analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating.
Tandem Mobi Now Compatible with Android Smartphones
Tandem Diabetes Care, Inc. has announced that its Tandem Mobi insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their personal devices, enhancing convenience and flexibility. The Mobi system, powered by Control-IQ technology, aims to broaden access to advanced diabetes management for a wider population.
Tandem Mobi Now Compatible with Android Smartphones
Tandem Diabetes Care has announced that its Tandem Mobi automated insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their Android devices, following its initial launch with iPhones in 2024. The system, recognized for its small size and driven by Control-IQ+ technology, aims to enhance convenience and accessibility for individuals with diabetes.
Tandem Diabetes Care Bond Deal Reshapes Funding And Valuation Picture
Tandem Diabetes Care recently completed a $265 million convertible bond offering, significantly altering its financing profile and balance sheet. While the bond deal provides capital for future projects, it also introduces potential share dilution. The stock's performance has been mixed, with short-term gains but longer-term declines, and it currently trades below analyst targets but near Simply Wall St's estimated fair value.
Tandem Diabetes Care Bond Deal Reshapes Funding And Valuation Picture
Tandem Diabetes Care recently completed a $265 million convertible bond offering, which significantly alters its financing profile and balance sheet. This capital injection provides the company with flexibility for future growth but also introduces potential share dilution. While the stock has seen short-term gains, its longer-term performance shows declines, and investors are advised to consider the bond's conversion terms and the company's management of these new funds against its current net loss.
Tandem Diabetes Care Receives Analyst Rating Upgrades
Tandem Diabetes Care, a San Diego-based medical device company, has recently received several rating upgrades and price target changes from industry analysts. The positive sentiment is primarily due to the company's innovative t:slim X2 Insulin Pump, which integrates continuous glucose monitoring and automated insulin delivery. This could boost investor confidence and increase product adoption, benefiting individuals with insulin-dependent diabetes.
Tandem Bests $1B Worldwide Sales
Tandem Diabetes Care Inc. has achieved over $1 billion in worldwide sales for the first time, driven by strategic changes including modernizing its salesforce, improving market access with a pharmacy benefit model, and continued product innovation. The shift to a pay-as-you-go pharmacy model for its Mobi pump significantly boosted revenue and investor confidence, leading to a substantial increase in stock value and a $265 million private placement. The company plans further innovations in 2026, including a tubeless Mobi pump and an advanced insulin algorithm.
3 Healthcare Stocks We're Skeptical Of
This article expresses skepticism about three healthcare stocks: Tandem Diabetes (TNDM), Select Medical (SEM), and Repligen (RGEN). The authors highlight concerns such as declining profitability, eroding returns on capital, high debt, and increased expenses for these companies. Despite the broader healthcare sector's recent gains, the article advises caution due to industry regulation and specific financial weaknesses identified in each stock.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Hold" by Brokerages
Tandem Diabetes Care (NASDAQ:TNDM) has received an average "Hold" recommendation from nineteen brokerages, with an average 1-year price target of $28.00. Despite beating Q4 earnings and revenue consensus, the company remains unprofitable, though institutional investors like Vanguard and Jennison have increased their stakes. Tandem Diabetes Care is a medical device company specializing in insulin delivery systems for diabetes.
Tandem Diabetes Care Raises $300 Million in 0% Convertible Notes, Adds Capped Calls to Curb Dilution
Tandem Diabetes Care completed a private offering of $300 million in 0.00% Convertible Senior Notes due 2032. The company also entered into capped call transactions to mitigate potential stock dilution, with net proceeds of approximately $290.7 million used to fund these calls and for general corporate purposes including potential acquisitions. The notes are convertible at about $36.99 per share, maturing on March 15, 2032.
Tandem Diabetes Care (TNDM) prices $300M zero-coupon convertible notes due 2032
Tandem Diabetes Care has completed a private offering of $300 million in 0.00% Convertible Senior Notes due 2032, raising approximately $290.7 million in net proceeds. These notes carry no regular interest and have an initial conversion price of about $36.99 per share, representing a 37.5% premium over the stock's price on February 24, 2026. The company intends to use the proceeds for general corporate purposes, including potential acquisitions and investments, and has used a portion for capped call transactions to mitigate dilution.
Tandem Diabetes Care Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends
Tandem Diabetes Care, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, reported a mixed financial performance with a net profit of -18.95 million USD for the half-year but strong quarterly net sales of 290.38 million USD and a 4.4% operating profit margin. Despite reduced raw material costs and efficient inventory management, the company faces challenges including a high debt-equity ratio, declining quarterly profits, and reduced cash and equivalents. While its short-term market returns have outperformed the S&P 500, its longer-term performance lags behind.
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
Tandem Diabetes Care reported record worldwide sales of $1.015 billion for the full year 2025, with fourth-quarter sales reaching $290.4 million. The company achieved a record gross margin of 58% in Q4 2025 and introduced a new pay-as-you-go pharmacy structure in the U.S. For 2026, Tandem Diabetes Care projects sales between $1.065 billion and $1.085 billion, anticipating double-digit pump shipment growth despite transitional headwinds from its new business model.
Envestnet Asset Management Inc. Cuts Stock Position in Tandem Diabetes Care, Inc. $TNDM
Envestnet Asset Management Inc. has reduced its stake in Tandem Diabetes Care, Inc. by 15% in the third quarter, selling 41,678 shares and now holding 236,332 shares valued at approximately $2.87 million. Despite beating quarterly EPS and revenue estimates, the medical device company remains unprofitable. Analysts currently have a "Hold" rating on Tandem Diabetes Care with a consensus target price of $28.00.
Is It Time To Reassess Tandem Diabetes Care (TNDM) After The Recent 43% Price Jump
Tandem Diabetes Care (TNDM) has seen a significant 43% price jump recently, sparking interest in its valuation despite a decline over the past year and five years. A Discounted Cash Flow (DCF) analysis suggests the stock is currently around 6.7% overvalued at US$26.90, while a Price-to-Sales (P/S) ratio analysis indicates it might be undervalued. The article also presents "Narratives" for investors to consider, offering both bull and bear case valuations based on different growth assumptions and risk factors.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care, Inc. announced the pricing of an upsized private placement of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The offering was increased from the previously announced $200.0 million. The net proceeds, estimated at $256.7 million, will be used for capped call transactions and general corporate purposes, including potential acquisitions.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care announced the pricing of an upsized private placement of $265 million in 0.00% Convertible Senior Notes due 2032. The net proceeds are estimated to be $256.7 million, or up to $290.7 million if an option for additional notes is exercised, and will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will not bear regular interest, mature on March 15, 2032, and have an initial conversion price of approximately $36.99 per share, representing a 37.5% premium over Tandem's common stock's last reported sale price.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care, Inc. announced the pricing of an upsized private placement of $265.0 million in 0.00% Convertible Senior Notes due 2032. The net proceeds of approximately $256.7 million will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will mature on March 15, 2032, and are convertible into cash, common stock, or a combination thereof, at the company's election, with an initial conversion price of approximately $36.99 per share.
